全文获取类型
收费全文 | 343篇 |
免费 | 24篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 72篇 |
妇产科学 | 1篇 |
基础医学 | 28篇 |
口腔科学 | 5篇 |
临床医学 | 28篇 |
内科学 | 142篇 |
皮肤病学 | 1篇 |
神经病学 | 6篇 |
特种医学 | 42篇 |
外科学 | 9篇 |
综合类 | 3篇 |
预防医学 | 11篇 |
眼科学 | 1篇 |
药学 | 7篇 |
肿瘤学 | 12篇 |
出版年
2023年 | 1篇 |
2021年 | 3篇 |
2019年 | 1篇 |
2018年 | 4篇 |
2017年 | 4篇 |
2016年 | 5篇 |
2015年 | 4篇 |
2014年 | 10篇 |
2013年 | 17篇 |
2012年 | 18篇 |
2011年 | 17篇 |
2010年 | 13篇 |
2009年 | 14篇 |
2008年 | 21篇 |
2007年 | 13篇 |
2006年 | 10篇 |
2005年 | 10篇 |
2004年 | 4篇 |
2003年 | 10篇 |
2002年 | 11篇 |
2001年 | 12篇 |
2000年 | 14篇 |
1999年 | 13篇 |
1998年 | 10篇 |
1997年 | 12篇 |
1996年 | 15篇 |
1995年 | 15篇 |
1994年 | 9篇 |
1993年 | 10篇 |
1992年 | 3篇 |
1991年 | 5篇 |
1990年 | 3篇 |
1989年 | 7篇 |
1988年 | 7篇 |
1987年 | 3篇 |
1986年 | 2篇 |
1985年 | 3篇 |
1984年 | 4篇 |
1983年 | 2篇 |
1982年 | 7篇 |
1981年 | 5篇 |
1980年 | 7篇 |
1979年 | 1篇 |
1977年 | 4篇 |
1976年 | 1篇 |
1975年 | 4篇 |
排序方式: 共有368条查询结果,搜索用时 0 毫秒
81.
Rheumatoid arthritis: explanatory power of specific radiographic findings for patient clinical status 总被引:1,自引:0,他引:1
Radiographs of the hands and wrists of 201 patients with rheumatoid arthritis (RA) were scored for erosion, joint space narrowing, and malalignment. The explanatory power of these findings for measures of clinical status was studied with stepwise multiple linear regression analyses. Radiographic scores explained 59.2% of variation in physical joint count deformity scores, 58.5% of variation in limited motion scores, 22.5% of variation in grip strength scores, 20.5% of variation in button test scores, and 13.5% of variation for the American Rheumatism Association (ARA) Functional Class. Malalignment scores best explained variation in physical deformity, limited motion, and button test scores; joint-space-narrowing scores best explained variation in grip strength; erosion scores best explained variation in ARA Functional Class. When age, duration of disease, erythrocyte sedimentation rate, and rheumatoid factor titer were included in the regression analyses, results were similar to those without these variables. Therefore quantitative scores of specific radiographic findings are in themselves explanatory for measures of clinical status. 相似文献
82.
83.
Zahra Pakbaz MD Marsha Treadwell PhD Hae‐Young Kim PhD Felicia Trachtenberg PhD Nagina Parmar PhD Janet L. Kwiatkowski MD Melody J. Cunningham MD Marie Martin RN Nancy Sweeters PNP Ellis J. Neufeld MD PhD Patricia J. Giardina MD Nancy Olivieri MD Robert C. Yamashita PhD Elliott Vichinsky MD 《Pediatric blood & cancer》2010,55(4):678-683
84.
85.
T R Kinney R W Helms E E O'Branski K Ohene-Frempong W Wang C Daeschner E Vichinsky R Redding-Lallinger B Gee O S Platt R E Ware 《Blood》1999,94(5):1550-1554
Previous studies have determined the short-term toxicity profile, laboratory changes, and clinical efficacy associated with hydroxyurea (HU) therapy in adults with sickle cell anemia. The safety and efficacy of this agent in pediatric patients with sickle cell anemia has not been determined. Children with sickle cell anemia, age 5 to 15 years, were eligible for this multicenter Phase I/II trial. HU was started at 15 mg/kg/d and escalated to 30 mg/kg/d unless the patient experienced laboratory toxicity. Patients were monitored by 2-week visits to assess compliance, toxicity, clinical adverse events, growth parameters, and laboratory efficacy associated with HU treatment. Eighty-four children were enrolled between December 1994 and March 1996. Sixty-eight children reached maximum tolerated dose (MTD) and 52 were treated at MTD for 1 year. Significant hematologic changes included increases in hemoglobin concentration, mean corpuscular volume, mean corpuscular hemoglobin, and fetal hemoglobin parameters, and decreases in white blood cell, neutrophil, platelet, and reticulocyte counts. Laboratory toxicities typically were mild, transient, and were reversible upon temporary discontinuation of HU. No life-threatening clinical adverse events occurred and no child experienced growth failure. This Phase I/II trial shows that HU therapy is safe for children with sickle cell anemia when treatment was directed by a pediatric hematologist. HU in children induces similar laboratory changes as in adults. Phase III trials to determine if HU can prevent chronic organ damage in children with sickle cell anemia are warranted. 相似文献
86.
Morris CR Kuypers FA Larkin S Sweeters N Simon J Vichinsky EP Styles LA 《British journal of haematology》2000,111(2):498-500
To determine the effects of L-arginine (L-Arg) supplementation on nitric oxide metabolite (NOx) production, oral L-Arg was given to normal controls, sickle cell disease (SCD) patients at steady state and SCD patients hospitalized with a vaso-occlusive crisis (VOC). L-Arg (0.1 g/kg) increased NOx formation by 18.8 +/- 68% in normal controls, whereas steady-state SCD patients demonstrated a paradoxical decrease in NOx of -16.7 +/- 4% (P = 0.004). In contrast, patients with VOC demonstrated a dramatic increase in NOx production by +77.7 +/- 103%, a response that was dose dependent. L-Arg appears to be the rate-limiting step in NOx production during VOC. Oral arginine may therefore benefit SCD patients by inducing an increase in NO production during VOC. 相似文献
87.
Jones A Granger S Brambilla D Gallagher D Vichinsky E Woods G Berman B Roach S Nichols F Adams RJ 《Pediatric radiology》2005,35(1):66-72
Background and purpose Ischemic stroke occurs in at least 11% of patients with homozygous sickle cell anemia (SCD) by the time they turn 20 years old. High risk associated with distal intracranial internal carotid (ICA) and proximal middle cerebral artery (MCA) stenosis can be detected by transcranial Doppler (TCD). TCD screening offers the possibility of reducing the risk of first stroke significantly based on a paradigm tested and proven to be effective in a stroke prevention trial in sickle cell anemia (STOP). Children with high flow velocity in the ICA and MCA of 200 cm/s time average mean of the maximum (TAMM) or higher had a 10% per year risk of first stroke that was reduced to <1% with regular red cell transfusion (reduction of hemoglobin S <30%). The clinical application of the STOP results could be enhanced if criteria for treatment could be found that are based on peak systolic velocity (PSV), the measure more commonly used in vascular ultrasound practice.Objective To compare PSV and end diastolic velocity (EDV) with TAMM for prediction of stroke and to derive PSV cutpoints for STOP protocol definitions of conditional and abnormal TCD. Using the STOP TCD and stroke outcome data to compare PSV and TAMM in terms of stroke prediction, PSV cutpoints comparable to those based on TAMM and used in STOP were derived. Because of their familiarity to the vascular ultrasound community, PSV cutpoints should be an important alternative to TAMM and may increase availability of screening and risk stratification for children with this disease.Materials and methods Data from 1,937 baseline TCD studies from STOP were correlated with stroke outcome in those not treated with transfusion. Stroke prediction was assessed with survival analysis using TAMM, PSV and EDV as continuous variables individually and then pair-wise in the same model, which contained 53 stroke events.Results PSV and EDV were highly correlated to the TAMM velocity (r=0.94). The multivariate model for prediction indicated that TAMM velocity was a better predictor than EDV, and PSV and TAMM were approximately equivalent. PSV cutpoints defining the two relevant STOP risk categories—conditional, which should lead to increased TCD surveillance, and abnormal, which should lead to strong consideration for treatment according to STOP—were derived taking into consideration known differences in measurements between the dedicated Doppler systems (TCD) used in STOP and the transcranial Doppler imaging (TCDI) systems commonly used in clinical practice. The recommended PSV cutpoint for conditional TCD is 200 cm/s, and for abnormal TCD triggering consideration for treatment is 250 cm/s.Conclusion Assuming TCDI equipment is used and the STOP protocol is applied, a PSV cutpoint of 200 cm/s is recommended as the threshold for increased TCD surveillance (comparable to a TCD TAMM of 170 cm/s in STOP); a PSV of 250 cm/s is recommended as the cutpoint at which, if confirmed in a second examination, chronic transfusion should be considered. Assuming the STOP scanning protocol is used, PSV is at least as good as TAMM and can be used to select children with SCD for treatment or increased surveillance to prevent first stroke. 相似文献
88.
TAM Kaandorp JJ Bax SE Bleeker J Doornbos EP Viergever D Poldermans EE van der Wall A de Roos HJ Lamb 《Journal of cardiovascular magnetic resonance》2010,12(1):7
Background
To assess the relationship between improved regional and global myocardial function in patients with ischemic cardiomyopathy in response to β-blocker therapy or revascularization.Materials and methods
Cardiovascular Magnetic Resonance (CMR) was performed in 32 patients with ischemic cardiomyopathy before and 8 ± 2 months after therapy. Patients were assigned clinically to β-blocker therapy (n = 20) or revascularization (n = 12). CMR at baseline was performed to assess regional and global LV function at rest and under low-dose dobutamine. Wall thickening was analyzed in dysfunctional, adjacent, and remote segments. Follow-up CMR included rest function evaluation.Results
Augmentation of wall thickening during dobutamine at baseline was similar in dysfunctional, adjacent and remote segments in both patient groups. Therefore, baseline characteristics were similar for both patient groups. In both patient groups resting LV ejection fraction and end-systolic volume improved significantly (p < 0.05) at follow-up. Stepwise multivariate analysis revealed that improvement in global LV ejection fraction in the β-blocker treated patients was significantly related to improved function of remote myocardium (p < 0.05), whereas in the revascularized patients improved function in dysfunctional and adjacent segments was more pronounced (p < 0.05).Conclusion
In patients with chronic ischemic LV dysfunction, β-Blocker therapy or revascularization resulted in a similar improvement of global systolic LV function. However, after β-blocker therapy, improved global systolic function was mainly related to improved contraction of remote myocardium, whereas after revascularization the dysfunctional and adjacent regions contributed predominantly to the improved global systolic function. 相似文献89.
Cerebral vasculitis--recognition, diagnosis and management 总被引:1,自引:0,他引:1
Scolding NJ; Jayne DR; Zajicek JP; Meyer PA; Wraight EP; Lockwood CM 《QJM : monthly journal of the Association of Physicians》1997,90(1):61-73
Cerebral vasculitis is a serious but uncommon condition which presents
considerable difficulties in recognition, diagnosis and treatment. We
studied eight consecutive patients in whom this diagnosis was made. Despite
the great diversity of symptoms and signs, we noted three clinical
patterns: (i) acute or sub-acute encephalopathy, (ii) a picture with some
similarities to multiple sclerosis ('MS-plus'), and (iii) features of a
rapidly progressive space-occupying lesion. The identification of these
patterns may help recognition of cerebral vasculitis. The diagnostic value
of four investigative procedures not previously studied in cerebral
vasculitis was assessed: ophthalmological examination using low-dose
fluorescein angiography with slit-lamp video microscopy of the anterior
segment (abnormal in 4/5 patients); spinal fluid oligoclonal band analysis
(abnormal in 3/6 patients); anti-neutrophil cytoplasmic antibody assay
(abnormal in 3/8 patients); and indium-labelled white-cell cerebral imaging
(positive in only one patient). Treatment was with steroid alone (n = 2) or
steroid with cyclophosphamide (n = 6). Seven patients responded clinically.
相似文献
90.
The binding of bovine factor XII to kaolin 总被引:7,自引:0,他引:7
Purified bovine factor XII was radiolabeled with iodine-125 and its binding to kaolin studied. Binding was rapid and was not readily reversible upon adding unlabeled factor XII. The optimum pH for binding was in the region of pH 5-7. The isoelectric point of factor XII was pH 5.7. High concentrations of urea or increasing the ionic strength of the medium did not inhibit binding. Polyvalent macromolecules, such as Polybrene and polylysine, were effective inhibitors of factor XII binding to kaolin. Polylysine caused the release of factor XII that had bound to the kaolin surface. 相似文献